期刊文献+

非布司他致剥脱性皮炎 被引量:4

Exfoliative dermatitis due to febuxostat
原文传递
导出
摘要 1例77岁男性患者因高尿酸血症给予非布司他40 mg口服、1次/d.用药当晚双手出现散在红色皮疹.用药第8天皮疹扩散至全身,因肺部感染当晚静脉滴注替卡西林钠克拉维酸钾 3.2 g.次日凌晨患者全身皮疹加重,伴瘙痒,停用非布司他和替卡西林钠克拉维酸钾.一次性静脉注射地塞米松2 mg.停用非布司他第4天患者全身皮肤潮红、干燥,伴刺痛瘙痒,静脉滴注地塞米松10 mg、1次/d.第6天患者全身皮肤脱落,呈剥脱样,累及范围达100%;第11天诊断为剥脱性皮炎,静脉滴注甲泼尼龙琥珀酸钠40 mg、1次/d,人免疫球蛋白20 g、1次/d;第16天患者全身皮肤干燥,仍有脱屑;第19天皮疹基本消失. A 77-year-old male patient with hyperuricemia received febuxostat 40 mg orally once daily.On the night of the first dose administration, red rash appeared on his hands.On day 8, the skin rashes progressively spread over his entire body.The patient received an IV infusion of ticarcillin disodium/clavulanate potassium 3.2 g due to his pulmonary infection on the night of the same day.The next morning his symptoms of rashes worsened and accompanied with pruritus.Febuxostat and ticarcillin disodium/clavulanate potassium were withdrawn.He was given a temporary intravenous injection of dexamethasone 2 mg.On day 4 of drug withdrawal, his whole body turned red, dry and accompanied with severe pain and pruritus.He received an IV infusion of dexamethasone 10 mg once daily.On day 6, his skin had exfoliation (100% of body surface area).On day 11,he was diagnosed with exfoliative dermatitis and received an IV infusion of methylprednisolone 40 mg once daily and human immune globulin 20 g once daily.On day 16, his systemic skin became dry with desquamation.On day 19, his erythra almost disappeared.
作者 许曼 谢诚
出处 《药物不良反应杂志》 CSCD 2017年第4期308-309,共2页 Adverse Drug Reactions Journal
关键词 非布司他 皮炎 剥脱性 Febuxostat Dermatitis exfoliative
  • 相关文献

参考文献5

二级参考文献28

  • 1曹兴梅.药源性剥脱性皮炎的发病机制及防治措施[J].中国现代药物应用,2007,1(4):67-68. 被引量:29
  • 2孙秋宁.药疹的首诊及治疗[J].中国全科医学,2005,8(6):473-473. 被引量:7
  • 3Sung J, Bochicchio GV, Joshim, et al. Adimission serum albumin is predictive of outcome in critically ill trauma patients[J ] .Am Surg, 2004, 70(12) : 1 099.
  • 4Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of fe- buxostat, a novel non-purine inhibitor of xanthine oxidase! xanthine dehydrogenase[ J]. Life Sci, 2005,76 (16) : 1835-47.
  • 5Abeles AM. Febuxostat hypersensitivity [ J 1. J Rheumatol, 2012,39 (3) :659.
  • 6Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 A- merican College of Rheumatology guidelines for manage- ment of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia [ J ]. Arthritis Care Res ( Hoboken), 2012,64 ( 10 ) : 1431-1446.
  • 7Frampton JE. Febuxostat: a review of its use iu the treat-ment of hyperuricaemia in patients with gout[ J]. Drugs, 2015,75 (4) :427-438.
  • 8Chou HY, Chen CB, Cheng CY, et al. Febuxostat-asso- ciated drug reaction with eosinophiha and systemic symp- toms (DRESS) [ J ]. J Clin Pharm Ther, 2015,40 (6) : 689 -692.
  • 9Cao WL, Yan WS, Xiang XH, et al. Prevention effect of allopurinol on post - endoscopic retrograde cholangiopan- creatography pancreatitis : a meta - analysis of prospective randomized controlled trials[J]. PLoS One,2014,9(9) : e107350.
  • 10Cao ZH, Wei ZY, Zhu QY, et al. HLA-B* 5801 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese [ J ]. Pharmacogenomics, 2012, 13 ( 10 ) : 1193- 1201.

共引文献36

同被引文献25

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部